Fluicell welcomes Sandra Tejedor
Sandra Tejedor, who recently finished her PhD at University of Valencia, now joins Fluicell as an Application Scientist,…
Fluicell enters into the world of regenerative medicine
Today, Fluicell takes a big step forward in the development of the company. Based on Biopixlar’s unique high-resolution…
07
May
2021
Researchers develop antibodies targeting ion channel hTRPV1, important for pain therapy
In a research article, published on April 16 in Science Advances, researchers from Oblique Therapeutics AB together with…
19
Apr
2021
Årsstämma 2021
English version follows below. Med anledning av den fortsatta smittspridningen av viruset som orsakar covid-19 kommer Fluicells årsstämma…
16
Apr
2021
CEO Newsletter 3, 2021
”Retreading old footsteps has never been a driving force for Fluicell” In the third issue of the CEO…
30
Mar
2021
Fluicell launches Biozone 6
We are launching Biozone 6, Fluicell’s new innovation for single-cell pharmacology that lets you perform drug testing and…
15
Mar
2021
Biopixlar advances: Towards printing heart cells
Biopixlar’s microfluidic technology is ideal for printing even the most sensitive cell types. Using cells received from Dr….
12
Mar
2021
Fluicell in Di Hållbart Näringsliv
“Building human tissues cell by cell”. In an interview with Di Hållbart Näringsliv, Fluicell’s CEO Victoire Viannay talks…
09
Mar
2021
Biopixlar in 3D bioprinting eBook
“Biopixlar is a high-resolution bioprinting platform that uses a proprietary molecular cell-binding process and open volume microfluidics technology…
04
Mar
2021